Signed by Governor Ned Lamont

Vote Smart's Synopsis:

Vote to pass a bill that establishes a $25 cap on the price of insulin.

Highlights:

• Requires the health commissioner, by November 1, 2020, to establish a working group to determine whether diabetic patients should be referred to a federally-qualified health center (Sec. 1). 

• Requires the working group to meet before January 11, 2021 (Sec. 1).

• Requires the working group to submit their recommendation for diabetic patients to a federally-qualified health center by May 1, 2021 (Sec. 1). 

• Authorizes pharmacists to immediately prescribe a 30-day supply of insulin or any other diabetic device to patients under the following circumstances (Sec. 3):

• The patient has less than a 7-day supply of insulin;

• The pharmacist determines the patient is in grave physical danger if they do not receive an adequate supply of insulin within 7 days; or

• The patient has not recently received a prescription for insulin.

• Requires Section 3 to take effect on January 1, 2021 (Sec. 3). 

• Prohibits insulin and glucagon drug costs from exceeding $25 for a 30-day supply (Sec. 13).

• Prohibits the cost of diabetic and ketoacidosis devices from exceeding $100 for a 30-day supply (Sec. 13). 

• Requires Section 13 to take effect on January 1, 2022 (Sec. 13).

• Requires group health insurance policies to provide coverage for the treatment of all types of diabetes, including (Sec. 14):

• Laboratory and diagnostic tests;

• Insulin and non-insulin drugs; 

• Diabetic-related devices; and

• Diabetic ketoacidosis devices.

• Requires Section 14 to take effect on January 1, 2022 (Sec. 14).

Full Bill Text

Vote Smart's Synopsis:

Vote to pass a bill that establishes a $25 cap on the price of insulin.

Highlights:

• Requires the health commissioner, by November 1, 2020, to establish a working group to determine whether diabetic patients should be referred to a federally-qualified health center (Sec. 1). 

• Requires the working group to meet before January 11, 2021 (Sec. 1).

• Requires the working group to submit their recommendation for diabetic patients to a federally-qualified health center by May 1, 2021 (Sec. 1). 

• Authorizes pharmacists to immediately prescribe a 30-day supply of insulin or any other diabetic device to patients under the following circumstances (Sec. 3):

• The patient has less than a 7-day supply of insulin;

• The pharmacist determines the patient is in grave physical danger if they do not receive an adequate supply of insulin within 7 days; or

• The patient has not recently received a prescription for insulin.

• Requires Section 3 to take effect on January 1, 2021 (Sec. 3). 

• Prohibits insulin and glucagon drug costs from exceeding $25 for a 30-day supply (Sec. 13).

• Prohibits the cost of diabetic and ketoacidosis devices from exceeding $100 for a 30-day supply (Sec. 13). 

• Requires Section 13 to take effect on January 1, 2022 (Sec. 13).

• Requires group health insurance policies to provide coverage for the treatment of all types of diabetes, including (Sec. 14):

• Laboratory and diagnostic tests;

• Insulin and non-insulin drugs; 

• Diabetic-related devices; and

• Diabetic ketoacidosis devices.

• Requires Section 14 to take effect on January 1, 2022 (Sec. 14).

Full Bill Text